→ Mylan and Amgen breezed through their advisory committee reviews on Thursday without any unexpected kickbacks for their two new knockoffs of a pair of Roche megablockbusters. Both won nods in unanimous votes, which is what you’d expect for drugs given a clean assessment by FDA insiders. Mylan was up with MYL-1401O, a biosimilar of Herceptin. Amgen, meanwhile, won applause for its copycat of Avastin.
→ CS Bio wants to build a new HQ building on the bayfront in Menlo Park, CA, according to a report in the San Jose Mercury News. The company says it plans to triple its work force in the next five years to about 300.
→ Alder BioPharmaceuticals $ALDR has raised $161 million as it preps for a BLA on its CGRP migraine therapy. The Bothell, WA-based biotech is building a commercial organization for their drug, which looks like it will compete against a range of rivals in the field.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription